Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. - Wikidata - awgldk - TriplyDB

Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.

Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.

http://www.wikidata.org/entity/Q34004770

about

Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation.Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis.Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review.Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.How do family medicine residents choose an anticoagulation regimen for patients with nonvalvular atrial fibrillation?

P2860

Q36064839-C2EE71A0-3899-4317-BECE-5CEE021058B8 Q36085531-226DE3B2-9072-48C6-9583-3E5CB9BE8D05 Q37197199-7EB8D817-4678-463A-8C40-36B482B48CC4 Q38713953-2816B0E7-C289-481F-99B8-AD779341E0D3 Q39157217-3FF96E19-116A-47F0-8E4A-2FA388457CE2 Q40218370-3A7C3839-E4BB-4D86-B10A-97BF4D290CAD

P2860

Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.

http://www.wikidata.org/entity/Q34004770

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Economic evaluation of apixaba ...... brillation in the Netherlands.

@ast

Economic evaluation of apixaba ...... brillation in the Netherlands.

@en

Economic evaluation of apixaba ...... brillation in the Netherlands.

@nl

type

label

Economic evaluation of apixaba ...... brillation in the Netherlands.

@ast

Economic evaluation of apixaba ...... brillation in the Netherlands.

@en

Economic evaluation of apixaba ...... brillation in the Netherlands.

@nl

prefLabel

Economic evaluation of apixaba ...... brillation in the Netherlands.

@ast

Economic evaluation of apixaba ...... brillation in the Netherlands.

@en

Economic evaluation of apixaba ...... brillation in the Netherlands.

@nl

P1433

Q34004770-29BA1B4E-582D-4734-B1CA-0E0B1FA6230D

P1476

Q34004770-DABCA545-2C53-46B5-B488-2652333A686D

P2093

Q34004770-2F962299-770E-4763-B373-14F7538D5830

Q34004770-3A17DDC0-CAD7-4EBA-9B59-956276281F6E

Q34004770-41804E37-4E21-4BED-826D-797FBB8B34D3

Q34004770-905DFD88-9C3D-4DB6-8511-C8F187975031

Q34004770-9AF4E14B-E287-4DB7-BC76-B6A03B42A176

Q34004770-A438A41E-723E-4582-9BA5-77FA3EA73196

P2860

Q34004770-0A844E6B-3B7E-4EFC-9BDC-2218825E0D97

Q34004770-1611E92D-CFB2-479D-ADEA-1AB647C1258E

Q34004770-1DB63FDF-4FCF-44C6-A3FA-BFC064A92687

Q34004770-1FF9D989-BC3D-4AAC-980F-8484712E1B11

Q34004770-2002B525-A622-4214-B8D5-0A7AB8A08DEC

Q34004770-3BFFF032-8272-47AE-9D54-D219C3638FD2

Q34004770-3EB46730-FCDE-46F6-86D2-EDA135056483

Q34004770-48A78F1A-1AE9-4973-8628-1B98F9AD932F

Q34004770-4AC38F3A-B19B-484F-B992-3F6C034498E3

Q34004770-4E1302C8-4FE3-4800-ADC1-E9D9D1462694

P304

Q34004770-25B85790-9C50-4E53-A38B-4946A0C64B01

P31

Q34004770-42FA57C4-AF55-47E7-A5D9-43ED62B520AB

P356

Q34004770-F9B80C48-D9ED-4E93-99F6-2717141AE779

P407

Q34004770-2990AE55-6762-49F9-A335-1C9F180AEEB0

P433

Q34004770-CE97BD2B-54C3-482E-8D30-FA2F01434A09

P478

Q34004770-D5BC9705-11DD-4239-B8A6-E81E96043DC4

P577

Q34004770-F5391BC4-C944-4C8A-AFC8-AFEFE62482E5

P5875

Q34004770-11AE677F-F1A5-46F2-81ED-C09D1E958F7A

P698

Q34004770-F3993AF1-A4F2-4AB2-864F-0F3211B86CD1

P921

Q34004770-93E73837-0A67-47A6-A07D-CF5BFD1FA816

P932

Q34004770-45719880-F9AD-4DD8-A6F1-534E3C8D8773

P356

JOURNAL.PONE.0103974

P1433

P1476

Economic evaluation of apixaba ...... brillation in the Netherlands.

@en

P2093

Hoa H Le

http://www.w3.org/2001/XMLSchema#string

Jelena Stevanović

http://www.w3.org/2001/XMLSchema#string

Maarten J Postma

http://www.w3.org/2001/XMLSchema#string

Marjolein Pompen

http://www.w3.org/2001/XMLSchema#string

Mark H Rozenbaum

http://www.w3.org/2001/XMLSchema#string

Robert G Tieleman

http://www.w3.org/2001/XMLSchema#string

P2860

Dabigatran versus warfarin in patients with atrial fibrillation

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Apixaban versus warfarin in patients with atrial fibrillation

Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry.

The dynamics of mortality in follow-up time after an acute myocardial infarction, lower extremity arterial disease and ischemic stroke.

Apixaban in patients with atrial fibrillation.

New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation.

Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach.

P304

e103974

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0103974

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264503171

http://www.w3.org/2001/XMLSchema#string

P698

25093723

http://www.w3.org/2001/XMLSchema#string

P921

P932

4122386

http://www.w3.org/2001/XMLSchema#string